Table 2. Adjusted Risk Differences for Probability of Comprehensive CVRF Assessment.
| Comprehensive CVRF assessment | Adjusted risk difference, % (95% CI)a | P value |
|---|---|---|
| Race | ||
| White | −5.7 (−6.4 to −5.0) | <.001 |
| Non White | 1 [Reference] | |
| Age, y | ||
| ≤60 | 1 [Reference] | |
| 61-65 | 2.2 (13-3.1) | <.001 |
| 66-70 | 2.4 (1.5-3.4) | <.001 |
| 71-75 | 1.5 (0.3-2.7) | .01 |
| >75 | −4.3 (−5.6 to −2.9) | <.001 |
| National Poverty Index above median | −0.6 (−1.2 to 0.1) | .08 |
| Disease stage | ||
| Low risk | 1 [Reference] | |
| Intermediate risk | 0.0 (−0.8 to 0.8) | .96 |
| High risk | −1.3 (−2.1 to −0.5) | .002 |
| Metastatic or node positive | −7.4 (−8.9 to −5.8) | <.001 |
| Baseline year | ||
| 2010-2011 | 1 [Reference] | |
| 2012-2013 | 6.3 (5.4-7.2) | <.001 |
| 2014-2015 | 11.1 (10.2-12.0) | <.001 |
| 2016-2017 | 15.2 (14.4-16.1) | <.001 |
| ASCVD/ADT statusb | ||
| ASCVD−/ADT− | 1 [Reference] | |
| ASCVD+/ADT− | 10.4 (9.5-11.3) | <.001 |
| ASCVD+/ADT+ | 12.3 (10.9-13.7) | <.001 |
| ASCVD−/ADT+ | 3.0 (2.1-3.9) | <.001 |
Abbreviations: ADT, androgen deprivation therapy; ASCVD, atherosclerotic cardiovascular disease; CVRF, cardiovascular risk factor.
a
Risk difference coefficients are interpreted as absolute percent difference in the probability of outcome. All coefficients were adjusted for other covariates in the model.
b
ASCVD−/ADT− indicates no history of ASCVD, not receiving ADT; ASCVD+/ADT−, history of ASCVD, not receiving ADT; ASCVD+/ADT+, history of ASCVD, receiving ADT; and ASCVD−/ADT+, no history of ASCVD, receiving ADT.